The CITYSCAPE trial is the first randomised trial of an anti-TIGIT therapy and provides evidence that targeting both TIGIT and PD-L1 molecules (tiragolumab plus atezolizumab) may improve anti-tumour activity by amplifying the immune response in advanced NSCLC patients [28]. The gene discussed is CD274; the disease is neoplasm.